Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

SWAG - Secure Web Application Gateway (formerly known as letsencrypt, no relation to Let's Encrypt™) sets up an Nginx webserver and reverse proxy with php support and a built-in certbot client that ...

Novo Nordisk is facing serious pressure from a powerful adversary. It still has plenty of leeway to penetrate its target market, for now. Investors should keep a close eye on this company.

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the anticipated 25%. The stock is down 42% from its June ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk, which generates more than half of its sales in the United States. Novo, which competes with U.S ...

Novo Nordisk er blevet 1.700 mia. kr. mindre værd på seks måneder – er Danmarks største virksomhed i krise? Novo Nordisk kan stadig sælge mere fedmemedicin, end den kan nå at producere, og annoncerer ...

Novo Nordisk, Other Firms Meet Danish PM to Discuss Trump Tariff Threats COPENHAGEN (Reuters) - Danish businesses are concerned about a possible trade conflict with the United States over ...

Among business leaders in the meeting were Lars Fruergaard Jorgensen, CEO of Novo Nordisk (NOVOb.CO), opens new tab, which generates more than half of its sales in the United States. Novo ...

Novo Nordisk shares are down more than 4% Friday after the company's semaglutide — the active ingredient in both its diabetes drugs Ozempic and Rybelsus, and its obesity treatment Wegovy — was ...